Compare PRLB & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | SGP |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 932.9M |
| IPO Year | 2011 | N/A |
| Metric | PRLB | SGP |
|---|---|---|
| Price | $57.34 | $26.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $53.00 | $47.00 |
| AVG Volume (30 Days) | ★ 203.4K | 82.4K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $6.89 | N/A |
| P/E Ratio | $69.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.20 | $24.71 |
| 52 Week High | $68.91 | $30.56 |
| Indicator | PRLB | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 53.08 |
| Support Level | $47.24 | $25.50 |
| Resistance Level | $68.91 | $30.02 |
| Average True Range (ATR) | 2.21 | 1.60 |
| MACD | -1.00 | -0.30 |
| Stochastic Oscillator | 0.68 | 29.00 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.